RSS feed

Publications by Geeta Gulati

19 publications found

Original articles

Gulati G, Broberg AM, Offersen BV (2024)
The Nordic Cardio-Oncology Society: mission and future goals
Eur Heart J (in press)
DOI 10.1093/eurheartj/ehae014, PubMed 38607440

Mecinaj A, Gulati G, Ree AH, Gravdehaug B, Røsjø H, Steine K, Wisløff T, Geisler J, Omland T, Heck SL (2024)
Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction
JACC CardioOncol, 6 (1), 83-95
DOI 10.1016/j.jaccao.2023.10.008, PubMed 38510299

Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, Van Der Meer P, Lyon AR, Farmakis D, Lee G, Boriani G, Wechalekar A, Okines A, Asteggiano R, Combes A, Pfister R, Bergler-Klein J, Lettino M (2022)
Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias
Eur Heart J Acute Cardiovasc Care, 11 (11), 865-874
DOI 10.1093/ehjacc/zuac107, PubMed 36226746

Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, Van Der Meer P, Lyon AR, Farmakis D, Lee G, Boriani G, Wechalekar A, Okines A, Asteggiano R (2021)
Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases
Eur Heart J Acute Cardiovasc Care, 10 (8), 947-959
DOI 10.1093/ehjacc/zuab056, PubMed 34453829

Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T (2021)
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
Circulation, 143 (25), 2431-2440
DOI 10.1161/CIRCULATIONAHA.121.054698, PubMed 33993702

Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storås TH, Ree AH, Gravdehaug B, Røsjø H, Steine K, Geisler J, Schulz-Menger J, Omland T (2018)
Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial
Eur Heart J Cardiovasc Imaging, 19 (5), 544-552
DOI 10.1093/ehjci/jex159, PubMed 29106497

Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T (2017)
Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
J Am Heart Assoc, 6 (11)
DOI 10.1161/JAHA.117.006513, PubMed 29118031

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T (2016)
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Eur Heart J, 37 (21), 1671-80
DOI 10.1093/eurheartj/ehw022, PubMed 26903532

Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T (2012)
Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
Cardiology, 123 (4), 240-7
DOI 10.1159/000343622, PubMed 23207160

Gulati G, Hole T, Eide E (2011)
[Infectious endocarditis in a Norwegian hospital 1997-2006]
Tidsskr Nor Laegeforen, 131 (2), 115-7
DOI 10.4045/tidsskr.09.0338, PubMed 21267025

Øye KS, Gulati G, Graff BA, Gaustad JV, Brurberg KG, Rofstad EK (2007)
A novel method for mapping the heterogeneity in blood supply to normal and malignant tissues in the mouse dorsal window chamber
Microvasc Res, 75 (2), 179-87
DOI 10.1016/j.mvr.2007.06.009, PubMed 17688890

Gulati G, Bodegard J (2005)
[Long term prognosis in relation to the presence of systolic heart murmurs in healthy middle-aged men]
Tidsskr Nor Laegeforen, 125 (9), 1157-8
PubMed 15880150

Review articles

Omland T, Heck SL, Gulati G (2022)
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review
JACC CardioOncol, 4 (1), 19-37
DOI 10.1016/j.jaccao.2022.01.101, PubMed 35492815

Broberg AM, Geisler J, Tuohinen S, Skytta T, Hrafnkelsdóttir ÞJ, Nielsen KM, Hedayati E, Omland T, Offersen BV, Lyon AR, Gulati G (2020)
Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer
Curr Heart Fail Rep, 17 (6), 397-408
DOI 10.1007/s11897-020-00486-8, PubMed 32979150

Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T (2013)
[Cardioprotective treatment during adjuvant cancer therapy]
Tidsskr Nor Laegeforen, 133 (17), 1832-6
DOI 10.4045/tidsskr.12.1514, PubMed 24042297

Other articles

López-Fernández T, Farmakis D, Ameri P, Asteggiano R, de Azambuja E, Aznar M, Barac A, Bayes-Genis A, Bax JJ, Bergler-Klein J, Boriani G, Celutkiene J, Coats A, Cohen-Solal A, Córdoba R, Cosyns B, Filippatos G, Fox K, Gulati G, Inciardi RM, Lee G, Mamas MA, Novo G, Plummer C, Psyrri A et al. (2023)
European Society of Cardiology Core Curriculum for cardio-oncology
Eur J Heart Fail (in press)
DOI 10.1002/ejhf.3102, PubMed 38059343

Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD (2022)
[Checkpoint inhibitor-induced myocarditis]
Tidsskr Nor Laegeforen, 142 (18)
DOI 10.4045/tidsskr.21.0817, PubMed 36511752

Gulati G (2022)
Cardioprotection in breast cancer patients: one size fits all?
Eur Heart J, 43 (27), 2570-2572
DOI 10.1093/eurheartj/ehab810, PubMed 34951626

Broberg AM, Tuohinen S, Skytta T, Geisler J, Hrafnkelsdóttir ÞJ, Smáradóttir A, Nielsen KM, Offersen BV, Jarfelt M, Gulati G (2020)
The Establishment of the Nordic Cardio-Oncology Society
JACC CardioOncol, 2 (2), 333-335
DOI 10.1016/j.jaccao.2020.04.004, PubMed 34396242